Nasdaq is proud to be a partner to a global community of healthcare leaders, including 98% of U.S. listed biotech companies. Our listed clients choose Nasdaq for our index inclusion opportunities, marketing and visibility platform, and continued public policy advocacy work on behalf our of issuer community. Approximately 900 healthcare corporate clients and more than 450 biotech/pharma companies use our in-house shareholder engagement and intelligence tools and governance solutions (as of May 2019).
2019 Biotech IPOs
Nasdaq has a thriving index business for listed companies to gain exposure to passive investors, which includes the Nasdaq Biotechnology Index (NBI), a market capitalization weighted index focused specifically on the biopharmaceutical industry.
Largest Biotech-Pharma IPOs in 2019
IPO Market Value: $3.3B
Gossamer Bio, Inc
IPO Market Value: $1.1B
IPO Market Value: $1.23B
In the first half of 2019, we listed 41 healthcare IPOs of which 6 healthcare companies have an IPO market cap of over $1 billion and total IPO proceeds of $4.6 billion.Head of Healthcare Listings